Humacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to Strong Sell

Humacyte (NASDAQ:HUMA) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Several other equities research analysts have also commented on HUMA. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. BTIG Research lowered their target price on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, March 27th. Finally, Benchmark lowered their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Humacyte presently has a consensus rating of “Moderate Buy” and an average price target of $7.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $0.65 on Friday. The firm has a market capitalization of $144.31 million, a PE ratio of -3.25 and a beta of 2.11. The company has a debt-to-equity ratio of 20.08, a current ratio of 3.69 and a quick ratio of 2.95. The business has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.21. Humacyte has a 12 month low of $0.55 and a 12 month high of $2.93.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.35 million. Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%. As a group, research analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC grew its position in shares of Humacyte by 16.6% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock worth $104,000 after acquiring an additional 8,500 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Humacyte by 50.3% in the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after acquiring an additional 11,411 shares in the last quarter. Independent Advisor Alliance grew its position in shares of Humacyte by 49.4% in the 3rd quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after acquiring an additional 11,991 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $28,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Humacyte by 21.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock worth $73,000 after acquiring an additional 13,175 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.